Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

October 12, 2017: By Jon Swedien

1 Ophthalmic NewsAzura Ophthalmics has completed a $16 million Series B funding round that will enable it to further develop its dry eye disease treatment candidates, the Israeli company announced Oct. 10.

Azura is developing a portfolio of compounds in combination with a novel drug delivery platform designed to treat meibomian gland dysfunction (MGD), the leading cause of dry eye disease, the company said.

The firm also is preparing for a Phase IIa trial of a drug therapy that has shown efficacy in an initial clinical proof of concept study.

The round was led by a syndicate of OrbiMed, TPG Biotech, and Brandon Capital’s Medical Research Commercialisation Fund, with participation from an existing investor, Ganot Capital.

The company also announced Oct. 10 that Anat Naschitz of OrbiMed, Heather Preston of TPG Biotech, and Chris Nave of Brandon Capital will join the company’s board of directors.

The board also includes Guy Katsav of Ganot Capital, Azura CEO Marc Gleeson, and Yair Alster, MD, Azura’s founder and chief technology officer.

Alster previously co-founded several companies, including Forsight Vision 4 (sold to Roche-Genentech), Forsight Vision 5 (sold to Allergan), and Notal Vision, a commercial stage company.

Gleeson spent 14 years at Allergan as vice president of global marketing for ophthalmology, and then he joined Oculeve.

Azura has also named Charles Bosworth, formerly of Allergan, as its chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales